LU102612B1 - Chalcone derivative prodrug containing mpeg and synthetic method as well as application thereof in the preparation of anti-nonalcoholic steatohepatitis drugs - Google Patents

Chalcone derivative prodrug containing mpeg and synthetic method as well as application thereof in the preparation of anti-nonalcoholic steatohepatitis drugs Download PDF

Info

Publication number
LU102612B1
LU102612B1 LU102612A LU102612A LU102612B1 LU 102612 B1 LU102612 B1 LU 102612B1 LU 102612 A LU102612 A LU 102612A LU 102612 A LU102612 A LU 102612A LU 102612 B1 LU102612 B1 LU 102612B1
Authority
LU
Luxembourg
Prior art keywords
compound
chalcone derivative
nonalcoholic steatohepatitis
containing mpeg
derivative containing
Prior art date
Application number
LU102612A
Other languages
German (de)
English (en)
Inventor
Peng Yu
Ridwan Kadir Ahmad
Xiangshun Kong
Dong Wang
Lianbo Zhao
Cen Xiang
Yu'ou Teng
Yufan Zhao
Original Assignee
Univ Tianjin Science & Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tianjin Science & Tech filed Critical Univ Tianjin Science & Tech
Application granted granted Critical
Publication of LU102612B1 publication Critical patent/LU102612B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33344—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing carbamate group
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33379—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing nitro group
    • C08G65/33386—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing nitro group cyclic
    • C08G65/33389—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing nitro group cyclic aromatic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterized by the type of post-polymerisation functionalisation
    • C08G2650/04—End-capping
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LU102612A 2020-04-17 2021-03-03 Chalcone derivative prodrug containing mpeg and synthetic method as well as application thereof in the preparation of anti-nonalcoholic steatohepatitis drugs LU102612B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010303437.8A CN111349230B (zh) 2020-04-17 2020-04-17 一种含peg查尔酮衍生物前药和合成方法及其在制备抗非酒精性脂肪肝炎药物中的应用

Publications (1)

Publication Number Publication Date
LU102612B1 true LU102612B1 (en) 2021-09-03

Family

ID=71196574

Family Applications (1)

Application Number Title Priority Date Filing Date
LU102612A LU102612B1 (en) 2020-04-17 2021-03-03 Chalcone derivative prodrug containing mpeg and synthetic method as well as application thereof in the preparation of anti-nonalcoholic steatohepatitis drugs

Country Status (2)

Country Link
CN (1) CN111349230B (zh)
LU (1) LU102612B1 (zh)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103755732B (zh) * 2014-01-23 2016-06-08 中山大学 邻苯基查尔酮类化合物及其制备方法和应用
CN104788669A (zh) * 2015-04-15 2015-07-22 天津科技大学 新型水溶性聚乙二醇偶联的羟基喜树碱衍生物及其应用
CN110143902B (zh) * 2019-06-12 2021-06-04 天津科技大学 含硒查尔酮衍生物Compound 1和合成方法及在抗非酒精性脂肪肝炎药物中的应用
CN110143890B (zh) * 2019-06-12 2020-12-22 天津科技大学 一种查尔酮衍生物和合成方法及其在制备抗非酒精性脂肪肝炎药物中的应用

Also Published As

Publication number Publication date
CN111349230A (zh) 2020-06-30
CN111349230B (zh) 2022-11-01

Similar Documents

Publication Publication Date Title
RU2769050C1 (ru) Кристаллическая форма и солевая форма соединения пиридоимидазола и соответствующий способ получения
JPH0528239B2 (zh)
CN113666824A (zh) 一种大麻二酚-2-丙酸酯及其应用
BR112012021911B1 (pt) processo para a produção de derivados de piripiropeno
JP2009504726A (ja) ヒドロキシベンズアミド誘導体とその製造方法、及びこれを有効成分として含有する化粧料組成物
CN110003304A (zh) 一种水溶性雷公藤甲素衍生物及其制备方法和用途
CN106478760B (zh) 具有抗肿瘤作用的三帖类衍生物tba-x及其制备方法和应用
LU102612B1 (en) Chalcone derivative prodrug containing mpeg and synthetic method as well as application thereof in the preparation of anti-nonalcoholic steatohepatitis drugs
CN106967143B (zh) 结构新颖的pyxinol衍生物及其制备方法和用途
CN110143890B (zh) 一种查尔酮衍生物和合成方法及其在制备抗非酒精性脂肪肝炎药物中的应用
CN105693815A (zh) 一种哌嗪修饰的乌索酸衍生物及其制备方法和应用
Ahmad et al. A facile method for synthesis of N-acyloxymethyl-5-fluorouracils, as a class of antitumor agents
CN106046105A (zh) 一种甘草次酸、阿魏酸和硒代蛋氨酸三元化合物的制备方法及应用
CN109206469B (zh) 甘草次酸衍生物及其制备方法和用途
CN108586480B (zh) 含异硫氰酸酯基的青蒿素衍生物及其应用
CN107698648B (zh) 含胆甾醇的萘酰亚胺类衍生物及其合成和应用
CN110183459A (zh) α-倒捻子素衍生物及其制备方法和应用
CN110143902B (zh) 含硒查尔酮衍生物Compound 1和合成方法及在抗非酒精性脂肪肝炎药物中的应用
CN109232334A (zh) 一种甲硫基甲酯的合成方法
CN107365265B (zh) 夹竹桃麻素水溶性前药、其制备方法、药物组合物及用途
CN109503697B (zh) 3-(l-苯丙氨酸)-五环三萜衍生物及其合成方法和应用
CN105017231B (zh) 多取代吲哚类他汀含氟修饰物及其用途
Qi et al. A solid-phase approach to DDB derivatives
CN110526955A (zh) 含异羟肟酸结构片段的18β-甘草次酸类化合物及其应用
Shun et al. Stepwise synthesis of 2, 3-O-dipalmitoyl-D-glyceric acid and an in vitro evaluation of its cytotoxicity

Legal Events

Date Code Title Description
FG Patent granted

Effective date: 20210903